Bristol-Myers Squibb and the California Institute for Biomedical Research (Calibr) have entered into a worldwide research collaboration to develop small molecule anti-fibrotic therapies, and an exclusive license agreement for BMS to develop, manufacture and commercialize Calibr’s preclinical compounds from the collaboration. Financial terms were not disclosed.   Calibr, a non-profit organization, brings expertise in identifying and optimizing small molecules with anti-fibrotic activity through i...